Tagged as: Byooviz

BYOOVIZ® (Ranibizumab-Nuna) Granted Interchangeable Status

Recently, Biogen and Samsung Bioepis’s ranibizumab biosimilar (BYOOVIZ) was granted interchangeable status by the U.S. Food and Drug Administration.  BYOOVIZ was deemed interchangeable to Genentech’s LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.  BYOOVIZ, the first FDA approved…

Read More

Biogen Launches BYOOVIZ (ranibizumab) in Canada

On March 1, 2023, Biogen Canada Inc. announced that BYOOVIZTM (ranibizumab injection), a biosimilar to Genentech’s LUCENTIS, is now available in Canada.  BYOOVIZ is an anti-VEGF (vascular endothelial growth factor) therapy approved for the treatment of various eye disorders, including neovascular age-related macular degeneration (AMD).  According to Biogen, AMD accounts…

Read More